Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Q1 2024 Earnings Presentation
38 slides from Day One Biopharmaceuticals's earnings presentation, May 6, 2024
Slide 1: Day One Biopharmaceuticals Targeted Therapies for People of All Ages
Day One Biopharmaceuticals Targeted Therapies for People of All Ages May 2024
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some
Slide 3: Cancer Therapies for People of All Ages
Cancer Therapies for People of All Ages Develop medicines for genomically-defined cancers Establish first-in-class position through rapid registration pathways Expand to adolescent and adult populations in parallel and pursue those opportunities with the same commitment we do for children Our Approa
Slide 4: Our Pipeline
1 OJEMDA has received accelerated approval by the U.S. Food and Drug Administration. † Pimasertib Phase 1 dose escalation and expansion trial previously completed. † † Includes patients ≥12 years of age. § Research collaboration and license agreement with Sprint Bioscience AB for exclusive worldwide
Slide 5: OJEMDA (tovorafenib) Relapsed or Refractory BRAF-altered pLGG
OJEMDATM (tovorafenib) Relapsed or Refractory BRAF-altered pLGG
Slide 6: OJEMDA Now Approved In The U.S.
OJEMDA Now Approved In The U.S. OJEMDA is the first and only FDA Approved therapy for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation *This indication is approved unde
Slide 7: pLGG Impact On Patients' Lives
pLGG Impact On Patients’ Lives Lily was diagnosed with an operable brain tumor at 5 months of age Lily, lives with pLGG.
Slide 8: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children
Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children pLGGs are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over the long term1 A Serious and Life-Threatening Disease For the majority of
Slide 9: Sources
Source: 1. Heitzer AM, Raghubar K, Ris MD, et al. Neuropsychological functioning following surgery for pediatric low-grade glioma: a prospective longitudinal study. J Neurosurg Pediatr. 2019;1-9. doi:10.3171/2019.9.PEDS19357. 2. Bryant R. Managing side effects of childhood cancer treatment. J Pediat
Slide 10: Overview U.S. Prescribing Information For OJEMDA
Overview U.S. Prescribing Information For OJEMDATM (tovorafenib) *This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial. INDICATION
Slide 11: Efficacy Summary From OJEMDA Prescribing Information
Efficacy Summary From OJEMDATM (tovorafenib) Prescribing Information Overall response rate (RAPNO-LGG) in 76 evaluable patients 51% Response (IRC) RAPNO-LGG n n (%) 95% CI ORR, n (%) BRAF fusion or rearrangement BRAF V600 mutation Prior MAPKi use MAPKi-naïve Median DOR, months Median TTR, months Ran
Slide 12: Safety Summary From OJEMDA Prescribing Information
Warnings and Precautions Hemorrhage Skin toxicity, including photosensitivity Hepatotoxicity Effect on growth Embryo-fetal toxicity Use in NF1- associated tumors Safety Summary From OJEMDATM (tovorafenib) Prescribing Information No boxed warnings or contraindications TEAEs Preferred Term, n (%) Any
Slide 13: Estimated BRAF-Altered pLGG Patient Population In The U.S.
Estimated BRAF-Altered pLGG Patient Population In The U.S. ~26,000 ~2,000-3,000 ~1,100 Recurrent/Progressive Total Addressable Patient Population per Year6 at Steady State* Incidence of Treatment-Eligible Frontline Patients4,5 Prevalence of Systemically-Treated Patients Under 251-5 Up to 75% of pLGG
Slide 14: What Physicians & Caregivers Are Looking For In A Therapy
What Physicians & Caregivers Are Looking For In A Therapy Effective in stopping or shrinking tumors Manageable safety profile Minimal disruption to child’s life What HCP’s are Seeking “The goal is not interfering with the child’s life.” – Ped Onc, Chicago Ad Board “Our time with our kids is precious
Slide 15: Product Profile Aligns With What Physicians Are Looking For
Product Profile Aligns With What Physicians Are Looking For In A Therapy Data from Pivotal Phase 2 FIREFLY-1 trial. Meaningful tumor stabilization or shrinkage may be possible with OJEMDA. In the clinical trial: 51% of children experienced tumor shrinkage by at least 25% 82% of children saw their tu
Slide 16: Comprehensive Approach For A Successful Launch
Comprehensive Approach For A Successful Launch SP, Specialty Pharmacy. Physicians Payers Patients & Families Pre-launch engagement to establish Day One & provide background information Plans in place for rapid engagement post-approval 89% 65% AIDED AWARENESS INTENT TO TREAT Dedicated & experienced s
Slide 17: Targeted Launch With Highly Experienced Field Team
Targeted Launch With Highly Experienced Field Team Deep oncology experience with relationships at top-tier accounts Targeting ~200 centers where 90% of pLGG patients receive treatment 18 Account Managers fully-dedicated to OJEMDA Institutional experience and existing relationships with key accounts
Slide 18: Patient Support Program Supporting Access
Patient Support Program Supporting Access DEDICATED PATIENT NAVIGATOR COPAY CARD PROGRAM PHONE & VIDEO CONSULTATIONS COVERAGE DELAY PROGRAM PATIENT ASSISTANCE PROGRAM COVERAGE INTERRUPTION SUPPORT
Slide 19: FIREFLY-2 / LOGGIC Pivotal Phase Trial of Tovorafenib in Frontline pLGG
FIREFLY-2 / LOGGIC Pivotal Phase 3 Trial of Tovorafenib in Frontline pLGG
Slide 20: FIREFLY-2/LOGGIC Pivotal Phase Trial Of Tovorafenib In Frontline pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib In Frontline pLGG Trial Design * COG or SIOPe-LGG regimen. Abbreviations: CHG, chiasmatic, hypothalamic glioma; DoR, duration of response; LGG, low-grade glioma; ORR, objective response rate; QoL, quality of life; QW, once weekly; SoC, standard o
Slide 21: FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib with Pimasertib
FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib as a Combination with Pimasertib
Slide 22: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor
Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 Extensive non-clinical and clinical developmen
Slide 23: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib
Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors KRAS or NRAS mutant BRAF non-V600 mutant MEK ERK RAF/ MEK/ERK PI3K/m TOR PI3K/m TOR Proliferation, survival Proliferation, survival Type II RAFi + MEKI Type II RAFi + MEKI Non V600 BR
Slide 24: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) Trial Design
NRASmut Selected tumors Pre-identified patients with advanced solid tumors and available clinical molecular profiling information. Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) Trial Design1 Abbreviations: BOIN, Bayesian Optimal Interval Design; BRAF, B-Raf proto-oncogene, serin
Slide 25: Summary
Summary
Slide 26: Financial Summary: DAWN
Financial Summary: DAWN All financial and share information is unaudited. PRV, Priority Review Voucher. $ Millions Three Months Ended 3/31/24 Three Months Ended 3/31/23 R&D Expense $40.2 $27.8 G&A Expense $26.6 $18.0 Net Loss $62.4 $42.4 Cash, cash equivalents and short-term investments as of March
Slide 27: Priorities as a Commercial-Stage Company
Priorities as a Commercial-Stage Company Expand awareness amongst physicians and establish broad coverage to enable patient access Establish OJEMDA as the standard of care for relapsed or refractory pLGG harboring a BRAF alteration Provide a positive and supportive experience when initiating OJEMDA
Slide 28: Appendix
Day One tas Appendi 28
Slide 29: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations
Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mutations Tablet and
Slide 30: Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (FIREFLY-1) Trial Design
June 5, 2023 data cutoff. 1 Wen PY, et al. J Clin Oncol. 2010;28(11):1963-1972. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 3 van den Bent MJ, et al. Lancet Oncol. 2011;12(6):583-593. Abbreviations: CBR, clinical benefit rate; IRC, independent review committee; C, cycle; D, day; LGG, lo
Slide 31: Data from Pivotal Phase FIREFLY-1 Trial
Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff
Slide 32: FIREFLY-1 Baseline Patient Characteristics
FIREFLY-1 Baseline Patient Characteristics June 5, 2023 data cutoff. *Includes 6 patients with BRAF duplication and 2 with BRAF rearrangement per fluorescence in situ hybridization or in situ hybridization. †Includes tumors that were extending into multiple regions of the brain, leptomeningeal disea
Slide 33: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG
Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG Maximum change in tumor size (%) Maximum change in tumor size (%) Maximum change in tumor size (%) RAPNO-LGG RANO-LGG RANO-HGG June 5, 2023 data cutoff. BOR, best overall response; CBR, clinical benefit rate; CI, confidence interva
Slide 34: Duration Of Tovorafenib Therapy For Patients With RAPNO-LGG Evaluable Lesions
Duration Of Tovorafenib Therapy For All Patients With RAPNO-LGG Evaluable Lesions June 5, 2023 data cutoff. Patients Overall treatment duration (months) 5.3 Months 13.8 Months Median time to response Median duration of treatment
Slide 35: Duration Of Tovorafenib Therapy For Patients With RANO-HGG Evaluable Lesions
Duration Of Tovorafenib Therapy For All Patients With RANO-HGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 3.0 Months 16.6 Months Median time to response Median duration of treatment
Slide 36: Duration Of Tovorafenib Therapy For Patients With RANO-LGG Evaluable Lesions
Duration Of Tovorafenib Therapy For All Patients With RANO-LGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 5.5 Months 14.4 Months Median time to response Median duration of treatment
Slide 37: Tumor Response Across Three Assessment Criteria Consistent Across Subgroups
Tumor Response To Tovorafenib Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment June 5, 2023 data cutoff. 1 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316.
Slide 38: Tovorafenib Safety Data (n=137)
Tovorafenib Safety Data (n=137) June 5, 2023 data cutoff. Treatment-emergent AEs ≥25% any grade in arms 1 & 2. AE, adverse event; ALT, Alanine transaminase; AST, aspartate aminotransferase; COVID-19, Coronavirus disease 2019; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; RTI, respiratory
Day One Biopharmaceuticals — Q1 2024 Earnings Presentation on 6ix